Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Paricalcitol in Pediatric Subjects with Stage 5 CKD
NCT01382212Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2011
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of paricalcitol oral solution in secondary hyperparathyroidism (SHPT), sponsored by AbbVie Inc.. Started Oct 2011; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01382212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01382212.